Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638220 · ClinicalTrials.gov registry record
Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
A clinical trial, sponsored by Travere Therapeutics.
- Completed
- Registry status
- 442
- Enrollment target
NCT02638220 is a clinical trial that has completed, run by Travere Therapeutics. The registered enrollment target is 442 participants.
The verdict
NCT02638220 has completed, sponsored by Travere Therapeutics.
- COMPLETED
- Registry status
- 442 participants
- Enrollment target
Study Summary
Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a promising avenue for disease detection and prevention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2015-09 |
| Est. Completion | 2021-02-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02638220
The ClinicalTrials.gov registry entry for NCT02638220 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02638220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02638220 about?
NCT02638220 is a clinical study titled "Cerebrotendinous Xanthomatosis (CTX) Prevalence Study". Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a promising avenue for disease detection and prevention.
What is the current status of trial NCT02638220?
This trial is currently completed. The enrollment target is 442 participants. The study started on 2015-09. Estimated completion is 2021-02-19.
Who is sponsoring clinical trial NCT02638220?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.